, 6b b,15b b-dihydroxyandrost-4-ene-3,17-dione (9) and 11a a,15b b-dihydroxypreg-4-ene-3,20-dione (10). Fermentation of 2 with R. stolonifer yielded two known metabolites, 11a a-hydroxypreg-4-ene-3,20-dione (11) and 7. Compounds 1-11 were screened for their cholinesterase inhibitory activity in a mechanism-based assay.
In continuation of our studies on the biotransformation of potential bioactive agents, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] we subjected pregnenolone (1) to fungal metabolism with fungi reported to effect hydroxylation of steroids at various positions, 13, 14) and as a result a series of transformed analogues 3-11 were obtained. Pregnenolone (1) is a major hormone in human nerve tissues. 15) Its therapeutic role in repairing defective neurons is well documented. 16) The most promising therapeutic strategy for activating the central nervous cholinergic functions has been the use of cholinomimatic agents. Hence AChE and BChE have long been an attractive target for rational drug design and discovery of mechanism-based inhibitors for the treatment of Alzheimer's disease. 17) The main function of AChE and BChE inhibitors is to boost the cholinergic function by increasing the endogenous level of acetylcholine. We have previously reported a number of natural and microbial transformed inhibitors of cholinesterase. 13) Compound 1, on fermentation with Cunninghamella elegans, yielded a major metabolite 3. The di-acetate derivative 3b of compound 3 exhibited inhibitory activity against the butyrylcholinesterase (BChE) (IC 50 ϭ92.3 mM). The incubation of 2 with C. elegans yielded metabolites 7 and 9, which showed some activity against the acetylcholinesterase (AChE) (IC 50 ϭ45 mM) and butyrylcholinesterase (BChE) (IC 50 ϭ99.5 mM), respectively.
Results and Discussion
Metabolism of pregnenolone (1) (C 21 H 32 O 2 ) by C. elegans for 6 d yielded a known metabolite 3, and two new hydroxylated metabolites 4 and 5 ( Fig. 1) . The structure of known trihydroxylated metabolite 3 was identified as 3b,7b,11a-trihydroxypreg-5-en-20-one by comparison of its spectral data with the literature values. 18) The new metabolite 4 was obtained as a white amorphous material. The IR spectral data displayed absorptions for free hydroxyl and ketonic moieties at 3374 and 1693 cm
Ϫ1
, respectively, while the UV spectrum showed only the weak absorption at 204 nm. The HR-FAB-MS of 4 exhibited a quasimolecular ion [MϪ18ϩNa] ϩ at m/z 363.3780 corresponding to the formula of C 21 C-NMR spectrum (broad-band decoupled, distortionless enhancement by polarization transfer (DEPT)) displayed resonances for 21 carbon atoms, including three methyls, four methylenes, ten methines, and four quaternary carbons. The OH-bearing methine proton signal at d 3.57 was assigned to H-3, which showed homonuclear coupling ( (Fig. 3) . The OH-bearing methine proton resonating at d (Fig. 4) . A signal at d 68.0 was assigned to C-11, based on HMBC correlations between H 2 -12 (d 2.20, 1.40) and C-11. The stereochemistry of OH at C-11 was assigned to be a (equatorial) on the basis of NOESY couplings between H-11 and H -19 (d 1.10) and H-18 (d 0.64) (Fig. 4) . Thus from the foregoing spectral studies, the structure of compound 5 was characterized as 3b,6b,11a-trihydroxypreg-4-en-20-one.
Fermentation of pregnenolone (1) by Gibberella fujikuroi for 12 d yielded two known metabolites 6 and 7 (Fig. 1) .
Comparison of the spectral data of metabolites 6 and 7 with the reported data led to their identification as known hydroxypregnenolones: 3b,7b-dihydroxypreg-5-en-20-one (6) and 6b,15b-dihydroxypreg-4-en-3,20-dione (7). 18, 19) Compound 2 when incubated with Cunninghamella elegans (TSY 0865) yielded four known oxidative metabolites, 1 and 8-10 ( Fig. 2) , while with Rhizopus stolonifer (TSY 0471) two known hydroxylated metabolites 11 and 7 (Fig. 2) were obtained. The structures of the known metabolites were identified as androsta-1,4-diene-3,17-dione (8), 6b,15b-dihydroxyandrost-4-ene-3,17-dione (9), 11a,15b-dihydroxypreg-4-ene-3,20-dione (10) and 11a-hydroxypreg-4-ene-3,20-dione (11) on the basis of spectral comparision. [20] [21] [22] Compounds 1-11 were screened against the cholinesterase enzymes. Diacetate derivative 3b of metabolites 3 and 9 exhibited inhibitory activity against butylcholinesterase with an IC 50 value of 92.3Ϯ0.5 and 99.5Ϯ0.7 mM, respectively, while compound 7 inhibited AChE activity with an IC 50 value of 45Ϯ0.4 mM. The galanthamine, a positive control was used in the assay, showed IC 50 values of 0.5Ϯ0.001 and 8.5Ϯ0.01 mM against the AChE and BChE, respectively. Hydroxylations at allylic C-6 and C-15 positions apparently enhanced the inhibition potential against the enzymes (compounds 7, 9), while in compound 3b, diacetate moieties seemed to be responsible for the enhanced inhibition of the enzyme.
Acetylcholinesterase is a key enzyme of cholinergic brain synapses and neuromuscular junctions. Its major biological role is the termination of impulse transmission by rapid hydrolysis of the cationic neurotransmitter acetylcholine. 23) According to the cholinergic hypothesis, the memory impairment in patients with senile dementia of Alzheimer's type results from a deficiency in cholinergic function in the brain.
17)
The role of butyrylcholinesterase in normal aging and brain diseased persons is still elusive. Recently, it has been observed that BChE is found in significantly higher quantities in Alzheimer's patients than in normal age-related non-demented brains. 
Experimental
General Experimental Procedures Melting points were determined by a Buchi 535 melting-point apparatus. Optical rotations were measured on a Jasco DIP-360 digital polarimeter, and a Hitachi U-3200 spectrophotometer was used for UV spectrophotometry. The IR spectra were obtained on a FT-IR 8900 or FT-IR Bruker vector-22 spectrophotometer in CHCl 3 . The 1 Hand 13 C-NMR spectra were recorded on a mixture of CDCl 3 and CD 3 OD on a Bruker AM 400 NMR spectrometer using the UNIX data system at 400 and 100 MHz, respectively. 2D experiments in CDCl 3 were made on the Bruker AM 400 NMR spectrometer. The EI-MS and HR-EI-MS [ion source energy (70 eV), ion source temperature 250°C] were recorded on a JEOL JMS 600 H mass spectrometer. FAB-MS spectra were obtained on a JEOL JMS-AX505WA. TLC was carried out on silica gel precoated plates (Merck, PF 254 : 20ϫ20 cm, 0.25 mm). Spots on TLC were detected by spraying ceric sulphate and vanillin solution, followed by heating. Column chromatography (CC) was performed on silica gel (70-230 mesh size). Compounds 1 and 2 were purchased from Fluka. 
General Fermentation and Extraction Conditions
The fungal media were transferred into conical flasks (100 ml each) and autoclaved at 121°C. Seed flasks were prepared from three-day old slants and fermentation was allowed for 2 d on a shaker at 25°C. The remaining flasks were inoculated from the seed flasks. After 2 d, pregnenolone (1) and pregnenolone acetate (2) were dissolved in acetone and transferred into each flask (12 mg/ml) and flasks were placed on a rotatory shaker (128 rpm) at 25°C for fermentation. Time course studies were carried out after 2 d and the transformation was analyzed on TLC. The culture media was filtered and extracted with CH 2 Cl 2 and ethyl acetate. The extract was dried over anhydrous Na 2 SO 4 , evaporated under reduced pressure, and the brown gummy crude was analyzed by TLC.
Fermentation of Pregnenolone (1) with Cunninghamella elegans (TSY 0865) Compound 1 (370 mg) was dissolved in 20 ml acetone and placed in 30 flasks for fermentation. All the media were filtered after 6 d of fermentation and extracted with dichloromethane. The CH 2 Cl 2 extract was evaporated under reduced pressure and a thick brown crude (1.02 g) was obtained, which was subjected to silica gel CC to afford compound 3 (104 mg) on elution with pet. ether-EtOAc (25 : 75), compound 4 (15 mg) on elution with pet. ether-EtOAc (22 : 78) and compound 5 (8.5 mg) on elution with pet. ether-EtOAc (30 : 70).
3b,7b,11a-Triacetoxypreg-5-en-20-one (3a): Metabolite 3 (20 mg) was treated with pyridine/Ac 2 O (2 : 1) and stirred (5 h) at r.t. The reaction mixture was diluted with CH 2 Cl 2 (18 ml) and shaken with 2% aqueous NaHCO 3 (15 ml) and 2% HCl (15 ml). The CH 2 Cl 2 extract was then dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude extract (17 mg) was then subjected to silica gel CC to afford compound 3a. 3b,7b-Diacetoxy-11a-hydroxypreg-5-en-20-one (3b): Metabolite 3 (10 mg) was treated with pyridine/Ac 2 O (2 : 1) and stirred (6 h) at r.t. The reaction mixture was diluted with CH 2 Cl 2 (18 ml) and shaken with 2% aqueous NaHCO 3 (15 ml) and 2% HCl (15 ml Table 1 .
Fermentation of Pregnenolone (1) with Gibberella fujikuroi (ATCC 10704) Compound 1 (300 mg) was dissolved in 20 ml acetone and equally distributed among 40 flasks and kept for fermentation. The media was filtered after 12 d, extracted with dichloromethane and evaporated under reduced pressure to obtain a thick brown crude (0.92 g). The crude obtained (0.92 g) was subjected to silica gel CC to obtain 6 (9.1 mg) on elution with pet. ether-EtOAc (60 : 40), and 7 (7.23 mg) on elution with pet. ether-EtOAc (50 : 50).
Incubation of Pregnenolone Acetate (2) with Cunninghamella elegans (TSY 0865) Four liters media of Cunninghamella elegans was prepared for incubation of pregnenolone acetate (2). Compound 2 (500 mg) was dissolved in acetone and fed into each flask (15 mg) and flasks were placed on a shaker for 8 d. A time-course study was also conducted after 2 d of incubation. The resulting mixtures were extracted with dichloromethane and transformations were detected through TLC. Incubation of Pregnenolone Acetate (2) with Rhizopus stolonifer (TSY 0471) Three liters media of Rhizopus stolonifer (TSY 0471) was prepared for incubation of pregnenolone acetate (2). Compound 2 (300 mg) was dissolved in acetone and fed into each flask (20 mg) and flasks were placed on a shaker for 12 d. After 12 d, all the flasks were filtered and extracted with dichloromethane and the resulting crude extract was analyzed by TLC. Crude extract (0.9 g) was subjected to column chromatography (silica gel) to afford two hydroxylated metabolites, 7 (11.2 mg) on elution with pet. ether-EtOAc (50 : 50) and 11 (12 mg) on elution with pet. ether-EtOAc (55 : 45).
In Vitro Cholinesterase Inhibition Assay Electric-eel AChE (EC 3.1.1.7), horse-serum BChE (E.C 3.1.1.8), acetylthiocholine iodide, butyrylthiocholine chloride, 5,5Ј-dithiobis [2-nitrobenzoic acid] (DTNB), eserine and galanthamine were purchased from Sigma Co. (St. Louis, MO, U.S.A.). Cholinesterase inhibiting activities were measured by the spectrophotometric method developed by Ellman et al. 23) Acetylthiocholine iodide and butyrylthiocholine chloride were used as substrates to assay AChE and BChE inhibition, respectively. The assay conditions and protocol were the same as described previously.
23)

Determination of IC 50 Values
The concentrations of test compounds that inhibited hydrolysis of substrates (acetylthiocholine and butyrylthiocholine) by 50% (IC 50 ) were determined by monitoring the effect of increasing concentrations of these compounds on the inhibition values. The IC 50 values were then calculated using the EZ-Fit Enzyme Kinetics program (Perrella Scientific Inc., Amherst, U.S.A.).
